Therapeutic Angiogenesis by Gene Transfer in Critical Limb and Myocardial Ischemia

Author(s): Peter Schratzberger, Rudolf Kirchmair, Peter R. Vale, Douglas W. Losordo.

Journal Name: Current Pharmaceutical Design

Volume 9 , Issue 13 , 2003

Submit Manuscript
Submit Proposal

Abstract:

Cardiovascular atherosclerotic diseases remain leading causes of morbidity and mortality in the world. Despite the significant progress that has been made in the management of these diseases using medical, surgical and percutaneous therapies over the last three decades, there remains a significant population of patients who are not optimal candidates for surgical or percutaneous revascularization. Substantial research has focused on the administration of angiogenic growth factors, either as recombinant protein or by gene transfer, to promote the development of supplemental collateral blood vessels that will constitute endogenous bypass conduits around occluded native arteries, a strategy termed “therapeutic angiogenesis”. While many cytokines have angiogenic activity, the best studied both in animal models and clinical trials are vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). This review will discuss gene transfer strategies for therapeutic angiogenesis in critical limb and myocardial ischemia.

Keywords: angiogenesis, gene transfer, myocardial ischemia, Cardiovascular atherosclerotic, percutaneous revascularization., vascular endothelial growth factor, vegf, fibroblast growth factor, therapeutic angiogenesis

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 9
ISSUE: 13
Year: 2003
Page: [1041 - 1047]
Pages: 7
DOI: 10.2174/1381612033455062
Price: $58

Article Metrics

PDF: 1